Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma

Affiliations

• ¹ Pediatric Hematology and Oncology, University Medical Center Hospital Hamburg-Eppendorf, Hamburg, Germany; Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg. f.knoerr@uke.de.
• ² Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Erasmus Medical Center, Sophia Children's Hospital, Rotterdam.
• ³ Princess Máxima Center for Pediatric Oncology, Utrecht.
• ⁴ Pediatric Hematology, Immunology, Oncology, Sorbonne université, Hôpital Armand Trousseau, APHP, Paris.
• ⁵ Pediatrics 5 (Oncology, Hematology, and Immunology), Olgahospital, Stuttgart.
• ⁶ Pediatric Hematology and Oncology, University Medical Center Hospital Hamburg-Eppendorf, Hamburg.
• ⁷ Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Dept. Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Dept. Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht.